Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes

Abstract

Abstract.BACKGROUND: This present study was designed to follow up 82 patients among 115 MDS patients registered in study ODK-0801 for 5 years, to analyze the relationship between the WT1 mRNA expression level and prognosis. OBJECTIVE: This study aimed to investigate the clinical utility of WT1 mRNA expression levels. METHODS: After study ODK-0801, we investigated the conditions of the same patients once a year, including any clinical and laboratory findings supporting the diagnosis, and treatment among the living patients. RESULTS: When we assessed the survival time of 82 MDS patients by WT1 mRNA expression level, there were significant differences between the < 500 and 10 4 copies/µg RNA groups and between the 500-10 4 and 10 4 copies/µg RNA groups for BM levels (p < 0.01). Examination of the time of freedom from acute myeloid leukemia (AML) transformation indicated that a high WT1 mRNA expression level (> 10 4 copies/µg RNA) was a strong prognostic factor for a short time to AML transformation. CONCLUSION:The results indicate that the tumorigenesis of MDS is likely to originate at the stem cell level, suggesting that the WT1 mRNA level measurement in the BM is an effective prognostic marker in patients with MDS.

Five‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single‐arm phase 2 trial

“…It has been reported that WT1 mRNA expression can be a useful marker for diagnosis and risk evaluation of MDS . Therefore, we measured WT1 mRNA expression levels to evaluate disease progression during AZA treatment.…”

“…It has been reported that WT1 mRNA expression can be a useful marker for diagnosis and risk evaluation of MDS. 17,18 Therefore, we measured WT1 mRNA expression levels to evaluate disease progression during AZA treatment. However, because there was no correlation between WT1 mRNA expression levels before treatment and therapy responses in the present study, WT1 may not be useful as a prediction marker for AZA response.…”

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

“…This is consistent with prior work that has associated WT1 expression with poor prognosis in MDS and AML. [63][64][65][66] More novel was the association between shorter OS and CD93 hypomethylation in our cohort and overexpression in an external MDS cohort, because CD93 is a transmembrane receptor implicated in the pathogenesis of several malignancies. [67][68][69] The role of CD93 in myeloid malignancies is relatively unknown.…”

The Wilms’ tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis

“…Kobayashi et al . found that elevated WT1 expression levels were also more prevalent in the high-risk group, as classified by IPSS-R categories [ 27 ]. In the different risk groups of MDS, high WT1 expression levels were 2 of 8 patients (25%), 10 of 29 (34.5%), 12 of 21 (57.1%), 9 of 11 (81.8%), and 11 of 13 (84.6%) in the very-low, low, intermediate, high, and very-high risk categories, respectively.…”

“…Kobayashi et al . [ 27 ] showed that the median OS of patients with WT1 mRNA expression levels of 500, 50000, 100000, 150000 copies were greater than 60.0, 45.0, 17.5 and 12.0 months, respectively. In the report of Nagasaki et al .…”